LISCure Biosciences Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 30

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $14.1M

  • Investors
  • 18

LISCure Biosciences General Information

Description

Developer of bacteria-mediated immunotherapy designed to treat tumors as well as cancer. The company's immunotherapy is used by combining drugs, consisting of seven pipelines of medicine and two pipelines of health-functioning food, enabling healthcare professionals to treat tumors as well as degenerative neurological, autoimmune and metabolic diseases.

Contact Information

Website
www.liscure.bio
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • C-801, 700, Daewangpangyo-ro
  • Bundang-gu
  • Seongnam, Gyeonggi 13488
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • C-801, 700, Daewangpangyo-ro
  • Bundang-gu
  • Seongnam, Gyeonggi 13488
  • South Korea
+82

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

LISCure Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC 19-Dec-2024 $14.1M Completed Generating Revenue
5. Later Stage VC (Series C) 14-Nov-2022 Completed Generating Revenue
4. Early Stage VC 28-Jul-2021 Completed Generating Revenue
3. Early Stage VC (Series B) 25-Feb-2021 Completed Generating Revenue
2. Early Stage VC (Series A) 01-Oct-2020 $1.76M $1.76M Completed Generating Revenue
1. Seed Round 25-Jul-2019 Completed Generating Revenue
To view LISCure Biosciences’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

LISCure Biosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of bacteria-mediated immunotherapy designed to treat tumors as well as cancer. The company's immunotherapy is
Drug Discovery
Seongnam, South Korea
30 As of 2025

Cambridge, MA
 

Stockholm, Sweden
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

LISCure Biosciences Competitors (14)

One of LISCure Biosciences’s 14 competitors is Vedanta Biosciences, a Venture Capital-Backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Vedanta Biosciences Venture Capital-Backed Cambridge, MA
Gesynta Pharma Venture Capital-Backed Stockholm, Sweden
Cardurion Venture Capital-Backed Burlington, MA
Bristol-Myers Squibb Corporation Princeton, NJ
Gilead Formerly VC-backed Foster City, CA
You’re viewing 5 of 14 competitors. Get the full list »

LISCure Biosciences Patents

LISCure Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025143685-A1 Leuconostoc falkenbergense lbmb321010 strain, and composition comprising same for preventing, alleviating or treating degenerative brain diseases Inactive 26-Dec-2023
WO-2025135871-A1 Levilactobacillus parabrevis lbmb320041 strain and composition comprising same for preventing, alleviating or treating degenerative brain diseases Inactive 20-Dec-2023
CA-3223757-A1 Composition for treatment of autoimmune diseases comprising lactobacillus sakei or extracellular vesicles derived therefrom as active ingredient Pending 07-Jul-2021
EP-4368193-A1 Composition for treatment of autoimmune diseases comprising lactobacillus sakei or extracellular vesicles derived therefrom as active ingredient Pending 07-Jul-2021
EP-4368193-A4 Composition for treatment of autoimmune diseases comprising lactobacillus sakei or extracellular vesicles derived therefrom as active ingredient Pending 07-Jul-2021 A61K35/747
To view LISCure Biosciences’s complete patent history, request access »

LISCure Biosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

LISCure Biosciences Investors (18)

Investor Name Investor Type Holding Investor Since Participating Rounds
DT & Investment Corporate Venture Capital Minority
Easy Asset Management Corporation Minority
IBK Securities Limited Partner Minority
InterValue Partners Venture Capital Minority
Roy Investment Partners PE/Buyout Minority
You’re viewing 5 of 18 investors. Get the full list »

LISCure Biosciences FAQs

  • When was LISCure Biosciences founded?

    LISCure Biosciences was founded in 2018.

  • Where is LISCure Biosciences headquartered?

    LISCure Biosciences is headquartered in Seongnam, South Korea.

  • What is the size of LISCure Biosciences?

    LISCure Biosciences has 30 total employees.

  • What industry is LISCure Biosciences in?

    LISCure Biosciences’s primary industry is Drug Discovery.

  • Is LISCure Biosciences a private or public company?

    LISCure Biosciences is a Private company.

  • What is LISCure Biosciences’s current revenue?

    The current revenue for LISCure Biosciences is .

  • How much funding has LISCure Biosciences raised over time?

    LISCure Biosciences has raised $47.5M.

  • Who are LISCure Biosciences’s investors?

    DT & Investment, Easy Asset Management, IBK Securities, InterValue Partners, and Roy Investment Partners are 5 of 18 investors who have invested in LISCure Biosciences.

  • Who are LISCure Biosciences’s competitors?

    Vedanta Biosciences, Gesynta Pharma, Cardurion, Bristol-Myers Squibb, and Gilead are some of the 14 competitors of LISCure Biosciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process